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Abstract
Innate immune activation has been attributed a key role in traumatic brain injury (TBI) and successive morbidity. In
mild TBI (mTBI), however, the extent and persistence of innate immune activation are unknown. We determined
plasma cytokine level changes over 12 months after an mTBI in hospitalized and non-hospitalized patients compared
with community controls; and examined their associations to injury-related and demographic variables at admission.
Prospectively, 207 patients presenting to the emergency department (ED) or general practitioner with clinically confirmed
mTBI and 82 matched community controls were included. Plasma samples were obtained at admission, after 2 weeks, 3
months, and 12 months. Cytokine levels were analysed with a 27-plex beads-based immunoassay. Brain magnetic
resonance imaging (MRI) was performed on all participants. Twelve cytokines were reliably detected. Plasma levels of
interferon gamma (IFN-c), interleukin 8 (IL-8), eotaxin, macrophage inflammatory protein-1-beta (MIP-1b), monocyte
chemoattractant protein 1 (MCP-1), IL-17A, IL-9, tumor necrosis factor (TNF), and basic fibroblast growth factor (FGF-
basic) were significantly increased at all time-points in patients compared with controls, whereas IFN-c-inducing protein
10 (IP-10), platelet-derived growth factor (PDGF), and IL-1ra were not. IL-17A and FGF-basic showed significant
increases in patients from admission to follow-up at 3 months, and remained increased at 12 months compared with
admission. Interestingly, MRI findings were negatively associated with four cytokines: eotaxin, MIP-1b, IL-9, and IP-10,
whereas age was positively associated with nine cytokines: IL-8, eotaxin, MIP-1b, MCP-1, IL-17A, IL-9, TNF, FGF-
basic, and IL-1ra. TNF was also increased in those with presence of other injuries. In conclusion, mTBI activated the
innate immune system consistently and this is the first study to show that several inflammatory cytokines remain increased
for up to 1 year post-injury.
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Introduction
The World Health Organization (WHO) has identifiedtraumatic brain injury (TBI) as a key societal challenge as
it emerges as the number one cause of death and disability
from 2020, with 2.5 million cases estimated to occur each year in
the European Union.1 More than 85% of TBIs are classified as
mild.2 Although the majority recover well after mild TBI
(mTBI), 10–20% experience long-lasting symptoms such as
headache, emotional distress, and problems with concentration
and memory.3,4
Given that even mild tissue injury can damage cells and release
or expose damage associated molecular patterns (DAMPS), we can
hypothesize that inflammation in the brain, which is detectable in
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systemic blood, could be an important pathophysiological mecha-
nism following mTBI.5
The interplay between central nervous system (CNS)-derived
inflammation and systemic inflammation is intricate. Recent evi-
dence suggests that cytokines orchestrate a complex interplay be-
tween peripheral leukocytes and chronically activated microglia,
especially if the blood–brain barrier is compromised after me-
chanical damage, as seen in TBI.6 Although activation of the innate
immune system is crucial for recovery after TBI, as it promotes
beneficial clearance of injured cells/cell debris, prolonged neu-
roinflammation has been shown to be detrimental, leading to pro-
gressive CNS degeneration.5,7 In experimental models, it was
shown that repeated mTBI caused systemic and neuroinflammation
associated with chronic behavioral deficits.8 In sports-related mTBI
an immediate activation of the innate immune system (interleukin 6
[IL-6], IL-12) has been observed with return to baseline after a
week.9 The long-term course of systemic inflammation and type of
cytokines present in blood in patients with mTBI has been evalu-
ated sparsely, with one study including 52 patients showing an
increase of IL-1b, IL-6, and monocyte chemoattractant protein 1
(MCP-1) over a 3-month period with association of MCP-1 to post-
concussion syndrome.10
Many patients with mild TBI are not admitted to hospitals and
are thus possibly underrepresented in clinical studies.11 Therefore,
the Trondheim Mild TBI study was designed to include patients
who were seen in the primary care setting for mTBI, in addition to
patients who were admitted to the hospital, with 1-year follow-up
of all patients.12 In addition, age-matched community controls were
included for the same length of the follow-up for comparison.
In the present study, we examined plasma levels of a wide range
of inflammatory biomarkers in patients with mTBI from admission
to 12 months after injury compared with age-, sex-, and education-
matched community controls over the same time period. We then
examined associations between injury-related and demographic
variables and cytokine levels in the acute phase.
We hypothesized that mTBI leads to increases in systemic cyto-
kines over a prolonged time period and that acute-phase inflamma-
tory cytokines are associated with injury-related and demographic
factors.
Methods
Ethics, participants, and recruitment
The Trondheim Mild TBI study is a large-scale prospective
cohort study with follow-up for 12 months in patients with mTBI
and matched controls, all between 16 and 59 years of age (Nor-
wegian National Ethics Approval: REK 2013/754). The upper age
limit was chosen due to the higher frequency of comorbidities in the
elderly. All participants, and guardians of participants between the
age of 16 and 18 years, provided informed consent. The cohort and
magnetic resonance imaging (MRI) follow-up have been described
in detail previously.12,13 All data were handled in accordance with
the STROBE checklist (Supplementary Fig. S1).
Patients were included in the study between April 1, 2014 and
December 5, 2015. Patients were prospectively recruited by con-
tinuous screening of computed tomography (CT) referrals and
patient lists from two emergency departments (EDs): St. Olavs
Hospital (Trondheim University Hospital), a regional Level 1
trauma center in Trondheim, Norway, and Trondheim Municipal
Emergency Clinic, a general practitioner-run, outpatient clinic.
Patients were included when having sustained a TBI categorized as
mild according to the WHO criteria: 1) Glasgow Coma Scale
(GCS) score 13–15 at presentation in the ED; 2) witnessed loss of
consciousness (LOC) <30 min, confusion, or post-traumatic am-
nesia (PTA) <24 h, or traumatic lesion on neuroimaging, and did
not meet any exclusion criteria. (Supplementary Table S1).14,15
Clinical information was obtained from patient interviews and
medical records. LOC was rated as present only if observed.
Duration of PTA was recorded as the time after injury for which
the patient had no continuous memory (< 1 h, or 1–24 h). GCS
score was assessed in the ED or inferred from the record. Presence
of injuries to parts of the body other than the head was recorded,
and dichotomized into ‘‘yes’’ or ‘‘no,’’ based on self-report and
records. Such injuries were cranial fractures; fractures of ex-
tremities, clavicles, and ribs; wounds; and sprains, dislocations,
and other soft-tissue injuries. Bruises and wounds that did not
need suturing were not included. Major trauma was an exclusion
criterion in the study.
Community controls, matched on age, sex, and years of educa-
tion were recruited among staff, friends, and families of staff and
patients. The same exclusion criteria as for the TBI patients were
used (Supplementary Table S1).
Magnetic resonance imaging protocol
MRI scans were acquired using a 3.0 Tesla Siemens Skyra MRI
scanner, software version E11C, with a 32-channel head coil. The
same MRI protocol was used for all participants; three-dimensional
(3D) volumes were obtained with T1-weighted (magnetization pre-
pared rapid acquisition gradient echo [MPRAGE]), T2-weighted,
fluid-attenuated inversion recovery (FLAIR), and susceptibility-
weighted imaging (SWI). An axial (2D) diffusion-weighted scan and
a diffusion tensor/kurtosis scan were also acquired. The clinical
scans were read by an experienced neuroradiologist according to
predefined criteria as described in a previous publication.13
Blood samples
Blood was acquired from patients with mTBI in the admission
phase, defined as within 72 h post-injury; 2 weeks (– 3 days);
3 months (– 2 weeks); and 12 months (– 1 month) after the injury.
For the community controls, blood was collected at inclusion
corresponding to the admission phase for the patients, and after 3
and 12 months. Plasma samples used in the current study were
obtained from whole blood collected in 5-mL tubes containing
ethylenediaminetetraacetic acid (EDTA), directly placed on ice,
and centrifuged within 30 min at 2000 x g for 10 min at 4C. Ali-
quoted plasma samples were immediately stored at -80C.
Cytokine analysis
The EDTA plasma samples were analyzed using a commercial
fluorescence magnetic bead-based immunoassay, with high-
sensitivity detection range and precision (Bio-Plex Human Cy-
tokine 27-Plex, Bio-Rad Laboratories, Inc., Hercules, CA, USA).
The following cytokines were analyzed: IL-1b, IL-1 receptor
antagonist (IL-1ra), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (C-X-C
motif chemokine ligand 8; CXCL8), IL-9, IL-10, IL-12, IL-13,
IL-15, IL-17, eotaxin-1 (C-C motif chemokine ligand 11;
CCL11), basic fibroblast growth factor (FGF-basic), granulocyte
colony stimulating factor (GCSF), granulocyte-macrophage col-
ony stimulating factor (GM-CSF), interferon gamma (IFN-c),
IFN-c-inducing protein 10 (IP-10; CXCL10), monocyte che-
moattractant protein 1 (MCP-1; CCL2), macrophage inflamma-
tory protein-1-alpha (MIP-1a; CCL3), macrophage inflammatory
protein-1-beta (MIP-1b; CCL4), platelet-derived growth factor-
BB (PDGF-BB), RANTES (CCL5), tumor necrosis factor (TNF),
and vascular endothelial growth factor (VEGF).
The analyses were performed according to the manufacturer’s
instructions. Briefly, plasma samples were diluted 1:4 in Sample
Diluent (Bio-Rad Laboratories, Inc.). A lower detection limit for
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the cytokines in the low picogram/milliliter range (<20 pg/mL for
all cytokines) was determined automatically by the software
based on the standard curve for each cytokine. Based on many
years of experience with the multi-plex assay and a low inter-
assay coefficient of variation (<11 for all cytokines), the samples
were run in single. All samples from this study were analyzed
using the same batch of the Bio-Plex assay and on each plate
randomly chosen sample sets from patients and healthy controls
were analyzed.
Under physiological conditions most of the cytokines in plasma
are either not detected or detected in very low amounts.16 Thus,
only cytokines that were present in methodologically and clinically
meaningful amounts, according to our previous experience,16 in
more than 75% of all samples during the observation period, were
selected for further study (n = 12, see Results section). The re-
maining 15 were regarded as negative and therefore not included in
further analyses.
Statistical analysis
Frequencies and percentages of demographic and clinical vari-
ables for the total number of participants with data available at a
minimum of one time-point were calculated.
Descriptive statistics (mean, standard deviation, median, inter-
quartile range, and range) of non-log transformed cytokine values
were calculated.
Cytokine data are presented as box plots. Mixed model ana-
lyses were performed to compare the time course of cytokine
levels from the admission phase to 12 months after injury for the
mTBI group versus the community control group. As there are no
available control data at the 2-week time-point, this time-point
was removed from the mixed model analyses, although the 2-
week patient data are retained in the box plots. Certain cytokine
concentrations were log-transformed due to large ranges and non-
normal distribution of the data (marked on plot legends and table
legends). The mixed model analyses were conducted with time,
group, and time-by-group interaction as fixed effects and a
subject-specific random intercept to account for within-subject
correlations. Mixed model analyses were performed for all cyto-
kines with and without controlling for heterogeneous variances.
All model fits were shown to be improved with heterogeneous
variances controlled for (Supplementary Table S2), thus all data
presented are derived from these models. Post hoc contrast ana-
lyses between patient and control groups were performed for all
cytokines that showed a main effect of group. For those showing a
time-by-group interaction effect, further post hoc contrast ana-
lyses were used to assess within-group changes for the mTBI
group between successive time-points.
Best-subset regression analyses were performed to determine
the combination of demographic (sex and age) and clinical (GCS
score, PTA duration, LOC, traumatic MRI findings) variables that
best predict admission-phase cytokine levels. The best model was
determined based on the lowest Akaike Information Criterion
(AIC). The cytokine values were first standardized at each time-
point, and then the best-subset regression analyses were per-
formed using the standardized biomarkers as outcome variables.
Regression coefficients based on non-standardized biomarker
values were also reported. In the patients with mTBI, we also
calculated the empirical group means and standard deviations of
cytokine levels for each categorical predictor used in the best-
subset regression analysis.
All tests were two-sided with significance determined at
p < 0.05. Post hoc contrast analyses of the mixed models were
Bonferroni corrected (significance level of group differences at
each time-point: 0.05/3 = 0.017; significance level of within-group
changes for the mTBI group between time-points: 0.05/3 = 0.017).
All statistical tests were calculated using R version 3.2.2.17
Descriptive statistics were calculated using R’s base package
functions. Mixed model analyses were performed using the nlme




In total, 379 patients with mTBI participated in the overall study.
Blood samples were provided from 207 patients for at least one
time-point and of these, 194 had brain MRI performed within 72 h.
(Fig. 1). Of the 86 community controls enrolled, 82 provided blood
samples for at least one time-point (Fig. 2).
FIG. 1. Identification, enrollment, and follow-up of patients
with mild TBI (mTBI). Flow chart of inclusion of patients with
mTBI into the Trondheim Mild TBI follow-up study, along with
progression of blood data available at each successive time-point.
CT, computed tomography; mTBI, mild traumatic brain injury.
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Demographic and injury-related characteristics of the mTBI and
control group showed that 63.3% of patients with mTBI were male
(Table 1). The majority had very mild injuries, with GCS scores of
15 in 76%; 52.7% were not observed with a LOC, most had PTA of
less than 1 h (69.1%), intracranial traumatic findings MRI at 72 h
were present in few (11.1%), and the majority (63.3%) did not
experience other injuries (Table 1). The most common other in-
juries were soft-tissue injuries.
Time course of plasma cytokine levels in patients
with mTBI from admission to 12 months after injury
compared with controls
Cytokines were grouped according to biological function or
class; pro-inflammatory IFNc and chemokines (Fig. 3), pro-
inflammatory interleukins (Fig. 4A–C), growth factors (Fig. 4D,E),
and anti-inflammatory regulator IL-1ra (Fig. 4F). Nine of the
twelve cytokines assessed showed significant differences between
the mTBI patient and control groups, whereas IP-10, PDGF, and
IL-1ra did not show an effect of group (Table 2). For the cytokines
showing a significant effect of group, contrast analyses to assess
group differences at each time-point revealed significant differ-
ences between patients with mTBI and controls at each time-point
assessed (Fig. 3 and 4, Table 3). A time-by-group interaction was
evidenced for FGF-basic and IL-17A, indicating that the time
course between patients and controls differed for those two cyto-
kines. Five of the cytokines (MIP-1b, MCP-1, TNF, IL-9, and IL-8)
showed significant differences of both group and time, but no time-
by-group interaction. PDGF showed a significant interaction of
time-by-group, but no main effect of group or time. Two cytokines
(IP-10 and IL-1ra) demonstrated no effects of group or time, nor a
time-by-group interaction (Table 2).
Lastly, for the cytokines IL17-A and FGF-basic, which showed
both a significant group effect and a significant time-by-group in-
teraction, post hoc contrast analyses were performed to assess
differences between time-points for patients with mild TBI
(Table 4). Both increased between admission and 3 months; how-
ever, there was no significant increase between 3 and 12 months.
Significant differences were observed also between admission and
12 months, indicating patient cytokine levels did not return to
control levels at 12 months.
FIG. 2. Identification, enrollment, and follow-up of community
controls. Flow chart of inclusion of community controls along
with progression of blood data available at each successive time-
point. Blood samples were drawn from community controls at
enrollment (admission) and 3-month and 12-month time-points
(not 2 weeks).
Table 1. Patient Characteristics
Patients with mild
TBI Patients Controls
N = 207 N = 82
Gender (%)
Males 131 (63.3) 46 (56.1)
Females 76 (36.7) 36 (43.9)
Age at inclusion
Mean age, years (SD) 32.4 (13.2) 33.02 (12.9)







Unobserved LOC 109 (52.7%)
Observed LOC 98 (47.3%)
PTA (%)
PTA <1 h 143 (69.0)
PTA 1-24 h 64 (31.0)
Traumatic intracranial finding on MRI at 72 h (%)
TAI only 6 (2.9)
Contusion only 3 (1.4)
Intracranial hematoma only 3 (1.4)
TAI and contusion 5 (2.4)
Contusion and hematoma 6 (2.9)




Soft-tissue injuries 41 (19.8)
Total number with percentages in parenthesis presented.
GCS, Glasgow Coma Score; LOC, loss of consciousness; MRI,
magnetic resonance imaging; PTA, post-traumatic amnesia; SD, standard
deviation, TAI, traumatic axonal injury.
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Association of cytokine levels at admission
with demographic and injury-related variables
Associations between the 12 cytokines at time of admission and
demographic and clinical predictors were calculated in an all-
subset multiple regression analysis with standardized beta coeffi-
cients (Fig. 5). Non-standardized beta coefficients and p-values are
presented in Supplementary Table S3 and exact values of cytokines
in Supplementary Table S4. The models of eotaxin, MIP-1b, IL-9,
and IP-10 included negative associations of MRI findings, meaning
those with MRI findings exhibited lower levels of inflammatory
markers than those with no MRI findings.
Age was included in the models for the majority of cytokines,
specifically: IL-8, eotaxin, MIP-1b, MCP-1, IL-17A, TNF, IL-1ra,
IP-10, and PDGF. The associations were positive for all cytokines,
indicating that inflammation markers increase as a function of in-
creasing age.
‘‘Other injuries’’ showed a strong positive effect on TNF, which
indicates that TNF levels are significantly higher in those with
injuries to other parts of the body. To ensure the group difference
between mTBI and controls (Fig. 3) was not due to other injuries,
we re-ran the time course linear mixed model including mTBI
patients without other injuries versus controls. The mTBI group
without other injuries had increased TNF levels compared with the
controls at 3 and 12 months, and a significant group and time effect
was present (Supplementary Tables S5 and S6). The increased TNF
level in the mTBI group in the acute phase was thus mainly due to
other injuries. But, during the first year TNF levels increased sig-
nificantly in the mTBI group without other injuries. These results
show that mTBI per se was associated with chronically elevated
TNF levels.
A negative effect of other injuries was also included in the model
for eotaxin. Re-running the time course linear mixed model with
the mTBI patients without other injuries versus controls uncovered
FIG. 3. Levels of IFNc and five chemokines for patients with mTBI and controls over time. IFNc, IL-8, eotaxin, MIP-1b, and MCP-1 were
significantly higher in patients than in community controls at all time-points. IP-10 was not significantly different between groups at any time-
point. Data are presented as box plots with median as line, borders, 25th and 75th percentile, and whiskers (value of the 25th and 75th percentile
+1.5 interquartile range). Points above and below the whiskers represent outliers. Asterisks (*) indicate significant group difference between
patients and controls at a particular time-point in the linear effect model. The p-value level is represented as follows:* <0 .05, ** <0.01, *** <0.001,
**** <0.0001. IFN-c, interferon gamma; IL-8, interleukin 8; IP-10, IFN-c-inducing protein 10; MCP-1, monocyte chemoattractant protein 1;
MIP-1b, macrophage inflammatory protein-1-beta; mTBI, mild traumatic brain injury. Color image is available online.
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that the mTBI group without other injuries contributed most to the
increased eotaxin levels in the acute phase. The mTBI patients
without other injuries had significantly higher eotaxin levels than
controls at all 3 time-points, and a significant group effect was
present (Supplementary Tables S5 and S6). The increased eotaxin
levels in mTBI can therefore be ascribed to the TBI alone.
LOC was included as a positive association in the IFNc model,
but a negative association in the MIP-1b and eotaxin models, in-
dicating that in those with observed LOC IFNc concentrations were
higher, whereas MIP-1b and eotaxin concentrations were lower.
GCS scores were included as negative associations in models of
eotaxin and MIP-1b, indicating those with lower GCS score (i.e.,
more severe injury) exhibited lower cytokine values. Lastly, sex
was included as a positive association in only the IFNc model, and
as a negative association in the eotaxin, IL-17A, FGF-basic, and
PDGF models. This indicates that female patients with mTBI ex-
hibited higher values of IFNc and lower values of the other four
cytokines mentioned above. PTA was not included in any of the
cytokine models.
Discussion
In this unique cohort of patients with mTBI, treated both in the
hospital and the primary health care setting, we showed a prolonged
increase in cytokines in blood, reflecting an inflammatory response
from admission to 1 year after mTBI compared with matched
healthy controls.
Prolonged activation of the systemic
immune system in mTBI
In contrast to previous studies investigating limited numbers of
cytokines, we used an unbiased assessment of 27 cytokines.10
FIG. 4. Levels of interleukins, TNF, growth factors, and IL-1ra for patients with mTBI and controls over time. IL-17A, IL-9, TNF,
and growth factor FGF-basic were significantly higher in patients than in community controls at all three time-points. No differences
were shown for growth factor PDGF and regulator IL-1ra. For IL-17A, FGF-basic, and PDGF, the group differences between patients
with mTBI and community controls increased throughout the 12-month observation period (x). Box plots, outliers, and group differences
are presented and calculated in the same manner as in Figure 3. x, significant time x group interaction in the linear effect model; FGF-
basic, basic fibroblast growth factor; IL, interleukin; IL-1ra, IL-1 receptor antagonist; mTBI, mild traumatic brain injury; PDGF,
platelet-derived growth factor; TNF, tumor necrosis factor. Color image is available online.
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Cytokines form part of a complex inflammatory network,20 which
has been shown to be associated with injury severity in moderate to
severe TBI, in both human and experimental studies.21,22 Our study
is, to the best of our knowledge, the first to show significant sys-
temic cytokine elevations persisting for 1 year in mTBI across a
pro-inflammatory cytokine network.23,24
To date, studies of cytokine expression patterns over time have
focused on patients with moderate to severe TBI demonstrating
slightly higher plasma concentrations in the acute phase post-
injury than observed in our study.22,24 Whereas long-term plasma
cytokine studies, to our knowledge, are lacking in patients with
severe TBI, autopsy studies have revealed that intracerebral in-
flammation leading to microglial activation can persist for years,
and we can thus only speculate that this inflammation would be
observable in plasma as well, comparable to patients with mTBI
in this study.7 In this study in mTBI, cytokine plasma levels were
generally low and lower than observed during severe TBI.24
However, persistent, low-grade inflammation, comparable to the
Table 2. Summary of Main Effects of Group and Time and the Interaction
of Group and Time for Each of the 12 Cytokines
Cytokines Group F-value (p-value) Time F-value (p-value)
Interaction (group-by-time)
F-value (p-value)
IFN-c F = 22.42, p < 0.0001 F = 1.55, p = 0.213 F = 2.99, p = 0.051
IL-8 F = 10.64, p 5 0.001 F = 7.83, p 5 0.0005 F = 2.00, p = 0.136
Eotaxina F = 8.90, p 5 0.003 F = 2.66, p = 0.071 F = 1.57, p = 0.210
MIP-1b F = 10.91, p 5 0.001 F = 4.34, p 5 0.014 F = 0.96, p = 0.382
MCP-1a F = 9.44, p = 0.002 F = 3.34, p = 0.037 F = 1.87, p = 0.155
IP-10a F = 3.75, p = 0.054 F = 0.82, p = 0.442 F = 0.05, p = 0.954
IL-17A F = 20.59, p< 0.0001 F = 14.38, p< 0.0001 F = 4.06, p 5 0.018
Il-9 F = 29.66, p< 0.0001 F = 10.00, p 5 0.0001 F = 0.17, p = 0.842
TNF F = 21.47, p< 0.0001 F = 6.30, p 5 0.002 F = 1.05, p = 0.351
FGF-basic F = 17.40, p< 0.0001 F = 14.67, p< 0.0001 F = 4.97, p 5 0.007
PDGF F = 2.80, p = 0.095 F = 1.35, p = 0.261 F = 4.99, p 5 0.007
IL-1raa F = 0.36, p = 0.698 F = 0.50, p = 0.481 F = 2.45, p = 0.088
aLog transformed data. Significant differences are bolded.
aLinear mixed model analysis.
Group: patients with mild TBI compared with community controls when time is not taken into account; Time: time course of cytokine concentrations
when group is not taken into account; Group-by-Time: interaction of Group and Time; a significant effect indicates the time courses of patients with mild
TBI and community controls significantly differed.
FGF-basic, basic fibroblast growth factor; IL, interleukin; IL-1ra, IL-1 receptor antagonist; IFN-c, interferon gamma; IP-10, IFN-c-inducing protein 10;
MCP-1, monocyte chemoattractant protein 1; MIP-1b, macrophage inflammatory protein-1-beta; PDGF, platelet-derived growth factor; TBI, traumatic
brain injury; TNF, tumor necrosis factor.
Table 3. Group Comparisons between Patients with Mild TBI and Community Controls at Each Time-point, for Each







IFN-c 1.4 [0.6 – 2.2] 1.0 [0.1 – 1.9] 2.3 [1.4 – 3.1]
p 5 0.0007 p = 0.023 p< 0.0001
IL-8 2.8 [0.04 – 5.5] 4.2 [1.2 – 7.1] 4.8 [2.2 – 7.4]
p = 0.047 p 5 0.006 p 5 0.0003
Eotaxinb 0.1 [0.02 – 0.2] 0.1 [0.05 – 0.2] 0.1 [0.05 – 0.2]
p 5 0.017 p 5 0.002 p 5 0.002
MIP-1b 9.3 [0.5 – 18.0] 11.5 [2.6 – 20.4] 14.4 [6.4 – 22.3]
p = 0.038 p 5 0.012 p 5 0.0004
MCP-1b 0.19 [0.06 – 0.32] 0.25 [0.010 – 0.329] 0.14 [0.03 – 0.26]
p = 0.04 p = 0.0008 p = 0.013
IL-17A 3.7 [1.1 – 6.4] 5.5 [2.8 – 8.2] 6.6 [4.1 – 9.1]
p 5 0.006 p< 0.0001 p< 0.0001
IL-9 19.4 [11.3 – 27.4] 20.2 [12.4 – 28] 20.9 [13.2 – 28.5]
p< 0.0001 p< 0.0001 p< 0.0001
TNF 8.0 [3.0 – 13.0] 10.7 [6.1 – 15.4] 10.5 [6.0 – 15.1]
p 5 0.002 p< 0.0001 p< 0.0001
FGF-basic 7.3 [1.3 – 13.3] 10.2 [4.4 – 16.0] 14.4 [8.8 – 20.1]
p 5 0.017 p 5 0.0006 p< 0.0001
aEstimate refers to mean group differences as estimated by the mixed model. CI is the 95% confidence interval of the estimated group difference.
bLog transformed data. Post hoc contrast analyses based on the linear mixed model. Significant differences are bolded.
FGF-basic, basic fibroblast growth factor; IL, interleukin; IFN-c, interferon gamma; MCP-1, monocyte chemoattractant protein 1; MIP-1b,
macrophage inflammatory protein-1-beta; TBI, traumatic brain injury; TNF, tumor necrosis factor.
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cytokine levels obtained in this study, has been described in one
prior study of patients with mTBI and chronic diseases with in-
flammatory components such as Alzheimer’s and multiple scle-
rosis, and has been attributed to long-term morbidity, such as
fatigue and mortality.10,25,26
A hallmark in this study is the prolonged activation of cytokines
over the 1-year follow-up period in patients with mTBI, compared
with matched community controls. This is in contrast to studies
showing acute but transient increase of plasma cytokines in mTBI.
In a study of blast-exposed military personnel, cytokines IL-6 and
TNF returned to baseline levels within hours,27 whereas in sports-
related concussion cytokines IL-6 and IL-12 returned to baseline
within 7 days.9 In children with concussion, TNF, IL-6, IL-1b, IL-
10, and several neuronal damage plasma markers returned to
baseline within days, whereas IL-8 remained increased for 3
months.28 Likewise, a recent study in 52 patients with mTBI
showed prolonged increase of IL-1b, IL-6, and MCP-1, combined
with a general increase in cytokine load in patients with mTBI in
comparison with healthy controls over a period of 3 months.10
Overall, few clinical studies have been conducted to evaluate the
Table 4. Comparisons between Time-Points in Patients with Mild TBI, for Each of the Cytokine Concentrations
Showing a Significant Group Effect and a Significant Group-by-Time Interaction
Admission – 3 months
Estimatea [95% CI] p-value
3 months – 12 months
Estimatea [95% CI] p-value
Admission – 12 months
Estimatea [95% CI] p-value
IL-17A 3.7 [2.3 – 5.2] -0.2 [-1.8 – 1.4] 3.5 [2.0 – 5.0]
p< 0.0001 p = 0.796 p< 0.0001
FGF-basic 7.3 [4.2 – 10.4] 2.5 [-1.0 – 5.9] 9.8 [6.4 – 13.2]
p< 0.0001 p = 0.157 p< 0.0001
aEstimate refers to mean group differences as estimated by the mixed model. CI is the 95% confidence interval of the estimated group difference.
Post-hoc contrast analyses based on the linear mixed model.Significant differences are bolded.
FGF-basic, basic fibroblast growth factor; IL, interleukin; TBI, traumatic brain injury.
FIG. 5. Cytokines at admission are associated with demographic and clinical variables. Cytokines were input into an all-subsets multiple
regression as outcome variables, and all demographic and clinical variables were input as possible predictor variables. Separate regressions
were performed for each cytokine, with the associations shown to improve model fit depicted as colored squares. Model fit was determined
based on the Akaike Information Criterion. Associations presented are the beta-values of the final model. A blank space indicates that the
predictor was not included in the final model. The direction and size of regression coefficient is represented according to the figure legend
color scheme, whereby increasingly positive associations are graded to red, and increasingly negative associations are graded to blue. The
nine cytokines colored in green correspond to those whose linear mixed models revealed a significant group difference between patients
and controls, whereas the three cytokines to the right (black) did not show significant group differences. All beta-values are standardized.
Non-standardized beta-values and p-values are presented in Supplementary Table S3. Baseline comparison for Sex was male. Baseline
comparison for GCS scores of 13–14 was a GCS score of 15. Baseline comparison for Observed LOC was ‘‘Unobserved LOC.’’ Baseline
comparison for PTA duration of between 1 and 24 h was PTA of less than 1 h. Baseline comparison for MRI findings was ‘‘No MRI
Finding.’’ Baseline comparison for presence of injuries to other parts of the body was ‘‘No Other Injuries.’’ GCS, Glasgow Coma Score;
LOC, loss of consciousness; MRI, magnetic resonance imaging; PTA, post-traumatic amnesia. Color image is available online.
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consequences of prolonged inflammation in TBI. Here, we show
that patients with mTBI experience a state of systemic low-grade
chronic inflammation, for up to 1 year after the initial injury, which
is much longer than reported previously and independent of trauma
beside the mTBI.
Almost all cytokines, which were increased in patients with
mTBI in this study, have been reported to be associated with TBI.
MCP-1 has been associated with post-concussion syndrome in
mTBI patients.10 IL-8 (CXCL8) has been reported as a key me-
diator of neuroinflammation in severe TBI,21 eotaxin (CCL11) has
been associated with chronic traumatic encephalopathy,29 and
MIP-1b has been shown to be induced early in sports concus-
sion.30,31 These chemokines induce production of the pro-
inflammatory cytokine IFN-c, which was increased in this study.
IFN-c has been shown to increase cell recruitment to an injured
brain and thus local inflammation.32,33 Pro-inflammatory inter-
leukins IL-17A34 and IL-9,35 as well as TNF36 are suggested to be
involved in neuroinflammation after experimental severe (IL-17A
and IL-9) and clinical repeated mTBI (TNF), by stimulating and
controlling recruitment of neutrophils.37 To our knowledge, IL-9
has not been reported in clinical studies assessing TBI patients,
yet. This may be due to pre-selection of known cytokines in
previous studies. Given the large IL-9 elevations in patients with
mTBI compared with controls in this study, further research into
IL-9’s relation to TBI is warranted. Growth factor FGF-basic has
been shown to increase neurogenesis, preserve blood–brain bar-
rier integrity, and enhance blood vessel proliferation, while sup-
pressing autophagy.38
Notably, although each cytokine separately may be of limited
pathophysiological importance for the clinical disease severity
and outcome, and may differ substantially between individuals,
the overall finding of sustained inflammation with an orchestra of
many cytokines acting together and via different pathways might
be of utmost importance. Crosstalk between the cytokines is fre-
quently not detected when reductionistic systems such as isolated
cells are used. We postulate that a holistic approach to under-
standing the neurobiological changes occurring in post-mTBI can
be obtained only by using complex panels of assays in an in vivo
situation, and that the possible implication to long-term neu-
roinflammation is a critical finding of our study that warrants
further investigation.
Associations between increased cytokine plasma
levels and injury-related and demographic variables
There were several findings from the best-subset regression
analyses that point to more severe injury being associated with
lower levels of cytokines in blood at admission. First, eotaxin, MIP-
1b, IL-9, and IP-10 were all negatively associated with traumatic
intracranial MRI findings, indicating that in all cases, visible
traumatic lesions resulted in lower systemic cytokine levels. This
finding was unsuspected. It may suggest that systemic low-grade
inflammation in patients with mTBI reflects disease severity not
obviously linked to neuroradiological findings, a fact reported in
other diseases such as febrile status epilepticus and brain swelling
in cerebral malaria.39,40 Likewise, more severe injury indicated by
lower GCS score was negatively associated with eotaxin and MIP-
1b. Although GCS score has been shown to be an important pre-
dictor of morbidity in severe TBI,41 it has shown relatively poor
prognostic utility in mTBI,42 and to our knowledge, its relation with
inflammatory markers has not been investigated. Thus the signifi-
cance of these findings remains to be explained.
On the other hand, LOC was positively associated with admis-
sion IFN-c. IFN-c is upregulated in the brain following TBI, but
there is ongoing discussion about whether IFN-c elevation is ben-
eficial or detrimental.43,44 A large positive association of other
injuries with TNF was demonstrated. These results are unsurpris-
ing, as TNF release has been reported in response to bone fractures
and virtually all forms of ischemia/reperfusion injury in the acute
phase.45,46 However, as TNF also was significantly increased in
patients without other injuries at 3 and 12 months, TNF probably is
associated with mTBI itself.
Age was associated with higher levels of the majority of cyto-
kines: IL-8, eotaxin, MIP-1b, MCP-1, IL-17A, TNF, IL-1ra, IP-10,
and PDGF. The impact of age on the immune system has been well
characterized, and our results confirm that older individuals expe-
rience generally higher levels of inflammation.47
Lastly, sex showed different cytokine expression pattern in male
compared with female patients. Although this phenomenon has
been observed in several clinical and experimental studies in other
diseases and is thought to be dependent on hormonal balances, our
findings should be regarded as hypothesis generating.48,49
Limitations
Inclusion of non-hospitalized patients led to considerable vari-
ation in time (up to 72 h) of obtaining the first ‘‘admission’’ blood
sample, as many patients first needed to be tracked down and in-
vited to participate. Thus, initial, time-critical cytokine kinetics
immediately following the injury might have been lost. However,
as systemic cytokine levels remained elevated and even increased
during the observation period in some cases (IL-17A and FGF-
basic), the initial kinetics and the significance thereof might be of
less relevance in comparison with the long follow-up period.
As can be seen from Figures 1 and 2, we did not obtain blood
samples from individuals at all time-points. Loss to follow-up is an
issue that poses problems for generalizing group differences be-
tween early and late time-points. However, using a linear mixed
model circumvents the majority of these issues with missing data.
Previous studies in TBI patients have reported absolute plasma
cytokine levels, which differ to levels reported in this study.31,50
Methodologically, it is impossible to compare absolute cytokine
levels when detection assays from different producers without
standardized reference controls are used.16 Hence, absolute cyto-
kine levels in this study should only be compared between patients
with mTBI and the matched healthy controls, whereas pattern of
expression and relative group differences are comparable between
studies.10 In this study, only 11% of patients had MRI findings.
Thus, regression analysis findings are based on relatively few pa-
tients and need to be verified in future studies.
Implications for diagnosis, follow-up and therapy
The distinct pattern of cytokine expression observed in this study
indicates a previously undocumented pattern of persistent inflam-
mation following mTBI for 1 year post-injury. Factors normally
used to grade severity of a TBI, such as GCS score, LOC, MRI
findings, and PTA, were not associated consistently with cytokine
expression patterns in this study. A biomarker especially for triage
of patients with mTBI to guide diagnostic procedures is warranted;
however, previous studies have demonstrated low specificity for
inflammatory markers for predicting, for example, CT findings.51
Thus, further studies are needed to investigate if the demon-
strated inflammatory state is caused by neuroinflammation, and
what are the clinical implications of prolonged inflammation with
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outcome, such as post-concussion syndrome, and potential for
manipulating it for improved outcome.
Conclusion
This prospective observational study including clinic outpatients
indicates that low-level systemic inflammation persists during
1 year post mild TBI as a high number of cytokines with different
functions and etiologies remain increased through the observation
period.
Long-term cytokine increase was not explained by injury se-
verity determined by MRI findings or other injuries beside mTBI,
which may imply that inflammation post mTBI may not solely be
caused by trauma per se or obvious pathology in the brain tissue.
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